These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25416754)

  • 1. Long-term persistence of zoster vaccine efficacy.
    Morrison VA; Johnson GR; Schmader KE; Levin MJ; Zhang JH; Looney DJ; Betts R; Gelb L; Guatelli JC; Harbecke R; Pachucki C; Keay S; Menzies B; Griffin MR; Kauffman CA; Marques A; Toney J; Boardman K; Su SC; Li X; Chan IS; Parrino J; Annunziato P; Oxman MN;
    Clin Infect Dis; 2015 Mar; 60(6):900-9. PubMed ID: 25416754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.
    Schmader KE; Oxman MN; Levin MJ; Johnson G; Zhang JH; Betts R; Morrison VA; Gelb L; Guatelli JC; Harbecke R; Pachucki C; Keay S; Menzies B; Griffin MR; Kauffman C; Marques A; Toney J; Keller PM; Li X; Chan IS; Annunziato P;
    Clin Infect Dis; 2012 Nov; 55(10):1320-8. PubMed ID: 22828595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.
    Keating GM
    BioDrugs; 2016 Jun; 30(3):243-54. PubMed ID: 27189459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against Herpes Zoster and Postherpetic Neuralgia.
    Oxman MN; Levin MJ;
    J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S228-36. PubMed ID: 18419402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M; Keating GM
    Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
    Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination to prevent herpes zoster in older adults.
    Gnann JW
    J Pain; 2008 Jan; 9(1 Suppl 1):S31-6. PubMed ID: 18166463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P; Rothberg MB
    Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.